WO2010111905A1 - 治疗2型糖尿病的药物组合物 - Google Patents
治疗2型糖尿病的药物组合物 Download PDFInfo
- Publication number
- WO2010111905A1 WO2010111905A1 PCT/CN2010/070910 CN2010070910W WO2010111905A1 WO 2010111905 A1 WO2010111905 A1 WO 2010111905A1 CN 2010070910 W CN2010070910 W CN 2010070910W WO 2010111905 A1 WO2010111905 A1 WO 2010111905A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- pharmaceutical composition
- salt
- metformin
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- composition for treating type 2 diabetes comprises
- the present invention relates to a pharmaceutical composition for the treatment of type 2 diabetes, in particular comprising (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoro Fixed dose of methyl-5,6,8-tetrahydro-imidazo[1,5-pyrazine-1-carboxylate or its salt and metformin or its salt (eg hydrochloride:)
- Type 2 diabetes is a chronic and progressive disease caused by the complex pathophysiology of dual endocrine defects involving insulin resistance and weakened insulin secretion.
- Treatment for type 2 diabetes generally begins with diet and exercise followed by oral anti-diabetic monotherapy.
- this regimen does not adequately control blood glucose during long-term treatment, which results in the need for combination therapy within a few years after diagnosis.
- co-prescription of two or more oral anti-diabetic drugs can lead to complex and difficult treatments for many patients employed.
- Combining two or more anti-diabetic agents into a single tablet provides a possible means of delivering combination therapies that do not increase the complexity of the patient's daily treatment regime.
- HYZAARTM is a combination of losartan potassium and hydrochlorothiazide
- VYTORINTM is a combination of simvastatin and ezetimibe.
- GlucovanceTM metalformin and glyburide
- AvandamentTM metalformin and rosiglitazone
- MetaglipTM metalformin and glipizide
- Metformin represents the only oral anti-diabetic agent that has been shown to reduce the overall burden of microvascular and macrovascular diabetic complications and prolong the lifespan of patients with type 2 diabetes.
- metformin treatment is often associated with weight loss in overweight patients and improvement in fat profile in patients with dyslipidemia.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of agents developed to treat or improve glycemic control in patients with type 2 diabetes.
- Drugs used to treat type 2 diabetes in current clinical trials include MK-0431, vildagliptin (LAF-237), saxagliptin (BMS-47718), P93/01 (Prosidon), SYR322 (Takeda), GSK823093, Roche0730699 , TS021 (Taisho), E3024 (Eisai) and PHX-1149 ( Phenomix).
- oral administration of vildagliptin to human type 2 diabetic patients has been found to reduce fasting glucose and postprandial glucose deviations associated with significantly reduced levels of HbAIC.
- DDP4 A review of the use of DDP4 in the treatment of type 2 diabetes can be found in the following publications: (1) H.-U.
- the present invention provides a pharmaceutical composition of a fixed dose combination of Compound A or a salt thereof and metformin prepared by a dry or wet treatment method.
- the pharmaceutical composition of the present invention provides immediate release of two active pharmaceutical ingredients Compound A or a salt thereof and metformin, and immediate release of Compound A or a salt thereof and slow release of metformin.
- the pharmaceutical composition of the present invention is in the form of a tablet, and particularly a film-coated tablet, and may also be other oral dosage forms such as capsules.
- the present invention also provides a method for preparing Compound A or a salt thereof by a dry or wet treatment method.
- Dry processing methods include dry compression and dry granulation, and wet processing methods include wet granulation.
- Another aspect of the invention provides a method of treating type 2 diabetes by administering a therapeutically effective amount of a pharmaceutical composition of the invention to a subject in need of such treatment.
- the present invention relates to a novel pharmaceutical composition comprising a fixed dose combination of Compound A or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof, a method of preparing the pharmaceutical composition, and treatment using the pharmaceutical composition The method of type 2 diabetes.
- the invention relates to a pharmaceutical composition comprising a fixed dose combination of Compound A or a pharmaceutically acceptable salt thereof and metformin hydrochloride.
- Compound A or its salt inhibited DPP4 activity longer than MK-0431, and the inhibition intensity was greater than MK-0431. Therefore, the composition of Compound A or a salt thereof and metformin or a salt thereof is clinically significant. Detailed description of the invention
- One aspect of the invention relates to a dosage form for the pharmaceutical administration of a fixed dose combination of Compound A or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof.
- the dosage form can be in powder or solid form and includes tablets, capsules, sachets and the like.
- a particular solid dosage form relates to a tablet containing a fixed one dose combination of Compound A or a pharmaceutically acceptable salt thereof and metformin hydrochloride (1,1 metformin hydrochloride).
- composition comprising Compound A or a salt thereof and metformin or a salt thereof (e.g., hydrochloride:) is clinically significant.
- the pharmaceutical composition comprises (1) Compound A or a pharmaceutically acceptable salt thereof, one of two active pharmaceutical ingredients; (2) metformin or a salt thereof, such as a hydrochloride salt, a second active pharmaceutical ingredient; and (3) a lubricant or a glidant.
- the pharmaceutical composition may further comprise one or more excipients selected from one or more binders (binding agents); one or more Diluent; one or more surfactants or wetting agents; one or more disintegration And one or more antioxidants.
- Pharmaceutically acceptable salts of Compound A include, but are not limited to, phosphates, hydrochlorides, sulfates, nitrates, hydrobromides, methanesulfonates, maleates, tartrates, succinates, acetates , trifluoroacetate, fumarate, citrate, citrate, besylate, benzoate, naphthalene sulfonate, lactate, malate.
- the dose concentration of Compound A or a salt thereof incorporated in the pharmaceutical composition of the present invention is from about 1 mg to about 500 mg of the active moiety.
- the dose concentration of Compound A or a salt thereof is from about 25 mg to about 250 mg of the active moiety.
- the discrete dose concentrations are 25, 50, 75, 100, 150, 200, 300, 400 and 500 mg of Compound A or its salt active fraction equivalent.
- the unit dose concentration of the active moiety of Compound A or a salt thereof incorporated in the fixed-dose combination drug combination of the present invention is 25, 50, 75, 100, 150, 200, 300, 400 and 500 mg.
- Compound A or a salt thereof has a dose concentration of 50 or 100 mg.
- the unit dose concentrations of metformin hydrochloride incorporated into the fixed dose combination of the invention are 250, 500, 625, 750, 850, 1000 and 1500 mg. These unit dose concentrations of metformin hydrochloride represent dose concentrations approved for commercial treatment of type 2 diabetes in China and/or the United States.
- a specific embodiment of the dose concentration of Compound A or a salt thereof and metformin or a salt thereof such as a hydrochloride salt is as follows:
- substance A or its salt e.g., phosphate 30.25 mg
- metformin hydrochloride 250 mg
- substance A or its salt e.g., phosphate 30.25 mg
- metformin hydrochloride 500 mg
- Compound A or a salt thereof e.g., phosphate 60.5 mg
- metformin hydrochloride 250 mg
- Compound A or its salt e.g., phosphate 60.5 mg
- metformin hydrochloride e.g., metformin hydrochloride
- the pharmaceutical composition of the present invention is prepared by a wet or dry treatment method.
- the pharmaceutical composition is prepared by a wet processing method.
- the pharmaceutical composition is prepared by a wet granulation process. In the wet granulation, high shear granulation or fluidized bed granulation can be applied. In one embodiment, the use of fluidized bed granulation has the advantage of providing tablets with higher radial strength.
- the pharmaceutical composition is prepared by a dry process.
- the pharmaceutical composition is prepared by direct compression or dry granulation.
- An embodiment of dry granulation is rolling.
- the pharmaceutical composition obtained by dry or wet treatment can be compressed into tablets, packaged or metered into sachets.
- the pharmaceutical composition contains one or more lubricants or glidants.
- the lubricant include magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, hydrogenated castor oil, and a mixture thereof.
- a preferred lubricant is magnesium stearate or sodium stearyl fumarate or a mixture thereof.
- the flow aid include colloidal silica, calcium phosphate, magnesium silicate, and talc.
- the pharmaceutical compositions of the invention optionally contain one or more binders.
- the binder include hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HMPC), hydroxyethylcellulose, starch 1500, polyvinylpyrrolidone (polypyrrolidone), and copolymerized olefins. Pyrone.
- a preferred binder is polyvinylpyrrolidone.
- compositions of the invention may also optionally contain one or more diluents.
- the diluent include mannitol, sorbitol, calcium dihydrogen phosphate dihydrate, microcrystalline cellulose, and powdered cellulose.
- a preferred diluent is microcrystalline cellulose.
- Microcrystalline cellulose can be obtained from several Suppliers, including Avicel PH 101, Avicel PH 102, Avicel PH 103, Avicel PH 105 and Avicel PH 200 manufactured by FMC Corporation.
- the pharmaceutical composition of the present invention may also optionally contain a disintegrant.
- the disintegrant may be one of several modified starches, modified cellulose polymers or polycarboxylic acids, such as crosslinked sodium carboxymethylcellulose, sodium starch glycolate, potassium bolconlin and methylol fibers. Calcium (CMC Calcium).
- the disintegrant is crosslinked hydroxymethylcellulose sodium.
- Crosslinked hydroxymethylcellulose sodium NF type A is commercially available under the trade name "Ac-di-sol".
- the pharmaceutical compositions of the present invention may also optionally contain one or more surfactants or wetting agents.
- the surfactant can be an anionic, cationic or neutral surfactant.
- Anionic surfactants include sodium lauryl sulfate, sodium dodecyl sulfonate, oleyl sulfate, and sodium laurate mixed with stearic acid and talc.
- Cationic surfactants include benzalkonium chloride and decyltrimethylammonium bromide.
- Neutral surfactants include glycerol monooleate, polyoxyethylene sorbitan fatty acid esters, polyvinyl alcohol and sorbitan esters.
- Embodiments of the wetting agent include poloxamers, polyoxyethylene methyl ethers, polyoxyethylene castor oil derivatives, and polyoxyethylene stearates.
- An antioxidant may optionally be added to the formulation to give it chemical stability.
- the antioxidant is selected from the group consisting of ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, tocopherol enriched natural extract, L-ascorbic acid and its sodium or calcium salt, ascorbyl palmitate, citric acid Propyl ester, octyl phthalate, dodecyl phthalate, butylated hydroxytoluene (oxime) and butylated hydroxyanisole (oxime).
- the antioxidant is ruthenium or osmium.
- a preferred dosage form of the pharmaceutical composition of the invention is a tablet prepared by a compression process.
- the tablet may be coated with a mixture of, for example, hydroxypropylcellulose and hydroxypropylmethylcellulose, which contains titanium dioxide and/or other colorants such as iron oxide, dyes and lakes; polyvinyl alcohol A mixture of (PVA) and polyethylene glycol (PEG) containing titanium dioxide and/or other colorants such as iron oxide, dyes and lakes; or any other suitable immediate release coating.
- the coating provides taste masking and additional stability to the final tablet.
- Commercially available coatings are supplied by Colorcon to Opadry® for the formulation of powder blends.
- sweeteners and/or flavoring agents can be added if desired.
- the pharmaceutical composition contains about 3 to 20% by weight of Compound A or a salt thereof as one of two pharmaceutically active ingredients; about 25 to 94% by weight is the first a pharmaceutically active ingredient of metformin or a salt thereof such as a hydrochloride; 0 to 35% of the binder; and about 0.1 to 10% by weight of the lubricant.
- the binder is polyvinylpyrrolidone or hydroxypropylcellulose, and the lubricant is magnesium stearate or sodium stearyl fumarate. In this subclass, the binder is polyvinylpyrrolidone, and a lubricant and sodium stearyl fumarate.
- the pharmaceutical composition optionally contains from about 0% to about 3% by weight of surfactant and/or from about 0% to about 70% by weight of diluent.
- the surfactant is sodium lauryl sulfate and the diluent is microcrystalline cellulose.
- the pharmaceutical composition of the present invention is prepared by a wet granulation method and comprises about 5 to 18% by weight of Compound A or a salt thereof, which is one of two pharmaceutically active ingredients; About 65 to 77% of the second pharmaceutically active ingredient is metformin or a salt thereof such as a hydrochloride; about 4 to 9% by weight of a binder; and about 1 to 2% by weight of a lubricant.
- the binder is polyvinylpyrrolidone or hydroxypropylcellulose, and the lubricant is magnesium stearate or sodium stearyl fumarate. In this subclass of classes, the binder is polyvinylpyrrolidone.
- the pharmaceutical composition optionally contains from about 0.5% to about 1% by weight of surfactant and/or from about 5% to about 15% by weight of diluent.
- the surfactant is sodium lauryl sulfate and the diluent is microcrystalline cellulose.
- composition envisioned for commercial development is as follows:
- the active ingredient is Compound A or a salt thereof; the binder is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, and the diluent is microcrystalline cellulose. , and the surfactant is sodium lauryl sulfate.
- the lubricant is magnesium stearate or sodium stearyl fumarate
- the diluent is microcrystalline cellulose
- the surfactant is sodium lauryl sulfate.
- the active ingredient is Compound A or a salt thereof; the binder is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, and the diluent is microcrystalline cellulose. , and the surfactant is sodium lauryl sulfate.
- the active ingredient is Compound A or a salt thereof; about 65% by weight of metformin hydrochloride; about 7% by weight of a binder; about 1 to 2% by weight of a lubricant; Approximately 9% by weight of diluent and/or about 0.5% by weight of surfactant is selected.
- the active ingredient is Compound A or a salt thereof;
- the binder is polyvinylpyrrolidone,
- the lubricant is magnesium stearate or sodium stearyl fumarate, and the diluent is microcrystalline cellulose.
- the surfactant is sodium lauryl sulfate.
- the active ingredient is Compound A or a salt thereof; the binder is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, and the diluent is microcrystalline cellulose. , and the surfactant is sodium lauryl sulfate.
- the active ingredient is Compound A or a salt thereof; the binder is polyvinylpyrrolidone, the lubricant is magnesium stearate or sodium stearyl fumarate, and the diluent is microcrystalline cellulose. , and the surfactant is sodium lauryl sulfate.
- metformin of the present invention or a salt thereof such as a hydrochloride may be either immediate or slow release.
- the pharmaceutical tablet composition of the present invention may further contain one or more additional formulation ingredients selected from excipients known in the art of various pharmaceutical preparations. Depending on the desired properties of the pharmaceutical combination, any of the ingredients may be selected individually or in combination based on their known use in preparing the tablet composition.
- additional formulation ingredients include, but are not limited to, diluents, compression aids, glidants, disintegrants, lubricants, perfumes, flavoring agents, sweeteners, and preservatives.
- tablette as used herein is intended to include compressed pharmaceutical dosage formulations of all shapes and sizes, whether coated or not.
- Materials which can be used for coating include hydroxypropylcellulose, hydroxypropylmethylcellulose, titanium dioxide, talc, sweeteners, colorants and flavoring agents.
- the pharmaceutical compositions of the invention are prepared by wet granulation (high shear and/or fluidized bed).
- Granulation is a method in which a binder is added to a granulation solution or added to a granulation cylinder to form granules.
- the steps involved in the wet granulation process include the following:
- step 1 (2) adding an optional disintegrant to step 1;
- a binder such as polyvinylpyrrolidone or hydroxypropylcellulose is dried and added to the granulation cylinder for short-term dry mixing, followed by the addition of water, with or without surface Active agent (such as sodium lauryl sulfate).
- surface Active agent such as sodium lauryl sulfate
- two active pharmaceutical ingredients are added to a granulator cartridge, and a granulation solution is added thereto by fluidization, the granulation solution consisting of an aqueous solution of a binder, with or without surface activity Agent
- the granules prepared by high shear granulation are dried in a tray or dried in a fluid bed dryer.
- the granules are dried in a fluid bed dryer;
- step 6 adding a lubricant or a glidant (such as magnesium stearate and sodium stearyl fumarate) to the mixture of step 6 in a suitable mixer;
- a lubricant or a glidant such as magnesium stearate and sodium stearyl fumarate
- the lubricant particle mixture of step 7 can be filled into a vial, sachet or capsule or compressed into the desired tablet shape;
- the resulting tablets can be film coated.
- the steps involved in the dry process include:
- step 1 (2) adding an optional disintegrant to step 1;
- step 2 (3) adding an optional binder and/or diluent to step 2;
- step 3 (4) adding a lubricant or a flow aid to step 3;
- step 4 can be filled into a vial, pouch or capsule or compressed into the desired tablet shape, or processed by a roller compressor;
- the size of the particles can be adjusted in a suitable mill if necessary;
- an optional diluent may be added to the resulting granules to improve compression properties
- step 7 adding an optional lubricant or glidant to the mixture of step 7;
- the lubricant particle mixture of step 8 can be filled into a vial, sachet or capsule or compressed into the desired tablet shape;
- the tablet obtained in step 5 or step 9 can be film coated.
- the invention also provides a therapeutically effective amount of a fixed dose combination pharmaceutical composition of the invention by oral administration of a subject in need of such treatment.
- the method of type 2 diabetes is a human.
- the pharmaceutical composition is in the form of a tablet, which may also be in the form of a capsule.
- Pharmaceutical compositions containing a fixed dose combination can be administered once daily (QD), twice daily (BID) or three times daily (TID). detailed description
- Example 1 Fixed dose combination of 50 mg of compound A and 500 mg of metformin hydrochloride / wet granulation per tablet
- Compound A and metformin hydrochloride are fed to a high shear granulator or a fluidized bed granulator.
- high shear granulation in addition to the polyvinylpyrrolidone binder, purified water containing sodium lauryl sulfate is added to the APIs (active pharmaceutical ingredient) over a period of 3 to 5 minutes.
- the wet material was either dried at 40 ° C or dried in a fluid bed dryer at an inlet temperature of 45-60 ° C for 3 to 6 minutes.
- purified water containing polyvinylpyrrolidone and sodium lauryl sulfate is added to the APIs over a period of 30 to 60 minutes.
- the wet material is dried in a fluid bed dryer at an inlet temperature of 45-60 °C. Then, the dried material is ground using a co-grinder to obtain fine particles. After milling, microcrystalline cellulose was added to the granules and mixed in a double shell mixer for 200 revolutions. Then, a lubricant (sodium stearyl fumarate) was added thereto and additionally mixed for 100 rpm. The lubricated mixture was compressed using a rotary tablet press to provide 675 mg of uncoated tablets.
- Opadry® II suspension polyvinyl alcohol, polyethylene) Alcohol, titanium dioxide and talc, with or without colorants, were applied to an increase in weight of about 2.5% to provide 692 mg of coated film tablets.
- 50 mg of the compound A in the formulation may also be a pharmaceutically acceptable salt of the compound A, for example, 60.5 mg of the compound A phosphate, and so on.
- Metformin hydrochloride may also be metformin or other pharmaceutically acceptable salts.
- Example 2 Fixed dose combination of 50 mg of Compound A and 850 mg of metformin hydrochloride per tablet - wet granulation
- Tablets were prepared by wet granulation using essentially the procedure of Example 1 to provide 1103 mg of uncoated tablets.
- the tablets are optionally coated with a 27.9 standard Opadry® II film formulation to provide 1131 mg of coated tablets.
- Example 3 50 mg of Compound A and 100 mg of metformin hydrochloride in fixed doses per tablet - wet granulation
- Microcrystalline cellulose (Avicel PH-102 ) 112.3mg
- Tablets were prepared by wet granulation using essentially the procedure of Example 1 to provide 1286 mg of uncoated tablets.
- the resulting tablets were optionally coated with Opadry® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide and talc, with or without colorants) to a weight gain of about 2.5% to provide 1319 mg coated film tablets.
- Opadry® II suspension polyvinyl alcohol, polyethylene glycol, titanium dioxide and talc, with or without colorants
- Compound A and metformin hydrochloride are fed to a high shear granulator or a fluidized bed granulator.
- high shear granulation purified water is added to the APIs in 3-5 minutes in addition to the polyvinylpyrrolidone binder.
- the wet material was either dried at 40 ° C or dried in a fluid bed dryer at an inlet temperature of 45-60 ° C for 3-6 minutes. In the case of fluidized bed granulation, it will contain polyvinylpyrrolidone within 30-60 minutes.
- Purified water is added to the APIs. The wet material is dried in a fluid bed dryer at an inlet temperature of 45-60 °C. Then, the dried material is ground using a co-grinder to obtain fine particles.
- Example 5 Fixed dose combination of 50 mg of Compound A and 1000 mg of metformin hydrochloride per tablet - wet granulation
- Compound A and metformin hydrochloride are fed to a high shear granulator or a fluidized bed granulator.
- high shear granulation purified water containing sodium lauryl sulfate was added to the APIs in 3-5 minutes in addition to the polyvinylpyrrolidone binder.
- the wet material was either dried at 40 ° C or dried in a fluid bed dryer at an inlet temperature of 45-60 ° C for 3-6 minutes.
- purified water containing polyvinylpyrrolidone is added to the APIs over a period of 30-60 minutes. The wet material is dried in a fluid bed dryer at an inlet temperature of 45-60 °C.
- the dried material is ground using a co-grinder to obtain fine particles.
- the microcrystalline cellulose is added Into the granules and mix them in a double shell mixer for 200 revolutions.
- a lubricant magnesium stearate
- the lubricated mixture was compressed using a rotary tablet press to provide 1286 mg of uncoated tablets.
- the resulting tablets were then coated with an Opadry® II suspension (polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc, with or without colorants) to a weight gain of about 2.5% to provide 1319 mg coated film tablets.
- Example 6 fixed dose combination of 100 mg of Compound A and 1000 mg of metformin hydrochloride per tablet - wet granulation
- Tablets were prepared by fluidized bed granulation using essentially the procedure of Example 1 to provide 1271.50 mg of uncoated tablets.
- Example 7 Fixed dose combination of 100 mg of compound A and 500 mg of metformin hydrochloride per tablet - wet granulation
- Tablets were prepared by fluidized bed granulation using essentially the procedure of Example 1 to provide 739.50 mg of uncoated tablets.
- Test Example 1 In vitro activity and selectivity of Compound A, MK-0431 Method:
- DPP4—Glo Buffer and equilibrate to room temperature before use. Pre-buffer frozen fluorescein detection reagent, suspend DPP4-Glo. Add ultrapure water to the substrate and mix gently to make 1 mM substrate. Put the fluorescein detection reagent into the brown bottle, add DPP4-Glo fluorescein detection reagent should dissolve in 1 minute, dissolve the test compound in DMSO to 50 times the final concentration, add 50 times concentration to each tube. Compound 2 L was added, 2 L DMSO was added to the reverse control and the blank control, 46 L Tris buffer was added to each tube, and 48 L Tris buffer was added to the blank control in each of the negative control and test tubes.
- Add 2 ⁇ ) ⁇ 4 enzyme mix by shaking and centrifuge the tube. Transfer all of the material in the tube to a 96-well plate at a ratio of 1:49 for the mixed substrate and DPP4-Glo. Mix the vibrations to mix thoroughly. Allow to stand at room temperature for 30-60 minutes before use, add 50 ⁇ L of DPP4-Glo. and substrate mixture to each 96-well plate well, seal the plate with sealing film, use a plate shaker at 300-500 The 96-well material was slowly mixed at rpm/30 s. The culture was incubated at room temperature for 30 minutes to 3 hours, and the chemical emission count was measured on a NOVOstar multi-function microplate reader.
- Table 2 shows that Compound A significantly inhibited the serum DPP4 activity of cynomolgus monkeys after a single oral administration, and its strength and duration of maintenance were better than the equivalent dose of MK-0431. 10 mg/kg of Compound A could induce serum DPP4 activity within 12 hours. The inhibitor is maintained above 75%.
- Test Example 3 Effect of Compound A and MK-0431 in combination with metformin in Wistar rats with genetic obesity and diabetes. Male Wistar rats aged 14 to 19 weeks were divided into 5 groups of 5 to 6 per group. Only, Compound A, MK-0431 (10 mg/kg body weight/day, orally), metformin (100 mg/kg body weight/day; mixed in a commercial feed at a ratio of 5 ppm) were administered for 14 days.
- Blood was taken from the tail vein, and blood glucose and hemoglobin A1 were measured by enzymatic method using a commercial kit (NC-ROPET, Nippon Chemiphar CO.). The results were expressed as the mean value of each group (n 5-6). Standard deviations were analyzed by Dunnett's test and are given in Table 3. Use a 1% significance level.
- Test Example 4 Glucose load study of compound A phosphate, MK-0431 phosphate and metformin in Wistar rats with hereditary obesity and diabetes The male mice of 13 to 14 weeks old were divided into 5 groups. A group of 5 were given Compound A phosphate, MK-0431 (30 mg/kg/day, orally) and metformin (100 mg/kg/day, orally) for 7 days. An oral glucose load test (2 g glucose/kg/5 ml, orally) was performed immediately after fasting overnight.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI1015469A BRPI1015469A2 (pt) | 2010-03-08 | 2010-03-08 | composicao farmaceutica para tratamento do diabetes tipo 2 |
US13/257,945 US8476272B2 (en) | 2009-03-31 | 2010-03-08 | Pharmaceutical composition for treatment of type 2 diabetes |
JP2012502429A JP5713990B2 (ja) | 2010-03-08 | 2010-03-08 | 2型糖尿病治療用の医薬組成物 |
KR1020117025744A KR101686265B1 (ko) | 2010-03-08 | 2010-03-08 | 타입 2 당뇨병 치료용 약학적 조성물 |
RU2011140785/15A RU2533560C2 (ru) | 2010-03-08 | 2010-03-08 | Фармацевтическая композиция для лечения диабета 2 типа |
EP10758007.8A EP2402342B1 (en) | 2010-03-08 | 2010-03-08 | Pharmaceutical composition for treatment of 2 type diabetes |
CN2010800141870A CN102365284A (zh) | 2009-03-31 | 2010-03-08 | 治疗2型糖尿病的药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910129595A CN101849944A (zh) | 2009-03-31 | 2009-03-31 | 治疗2型糖尿病的药物组合物 |
CN200910129595.X | 2009-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010111905A1 true WO2010111905A1 (zh) | 2010-10-07 |
Family
ID=42801733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/070910 WO2010111905A1 (zh) | 2009-03-31 | 2010-03-08 | 治疗2型糖尿病的药物组合物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US8476272B2 (zh) |
CN (2) | CN101849944A (zh) |
WO (1) | WO2010111905A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI494313B (zh) * | 2010-12-29 | 2015-08-01 | Jiangsu Hengrui Medicine Co | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108026529A (zh) * | 2015-09-30 | 2018-05-11 | Ionis制药公司 | 组合疗法 |
CN108144065B (zh) * | 2016-12-06 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 一种dpp-4抑制剂的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1391890A (zh) * | 2002-08-05 | 2003-01-22 | 成都恒瑞制药有限公司 | 口服盐酸二甲双胍缓释剂及其制备方法 |
CN1478770A (zh) * | 2002-08-29 | 2004-03-03 | 中国科学院上海药物研究所 | 一类1,3-二羰基化合物及它的制备和用途 |
CN101277719A (zh) * | 2005-09-29 | 2008-10-01 | 第一三共株式会社 | 包含胰岛素增敏剂的药剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US20060052382A1 (en) * | 2002-12-20 | 2006-03-09 | Duffy Joseph L | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
EP1962827A4 (en) * | 2005-12-16 | 2011-02-16 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4-INHIBITORS WITH METFORMIN |
-
2009
- 2009-03-31 CN CN200910129595A patent/CN101849944A/zh active Pending
-
2010
- 2010-03-08 US US13/257,945 patent/US8476272B2/en not_active Expired - Fee Related
- 2010-03-08 WO PCT/CN2010/070910 patent/WO2010111905A1/zh active Application Filing
- 2010-03-08 CN CN2010800141870A patent/CN102365284A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1391890A (zh) * | 2002-08-05 | 2003-01-22 | 成都恒瑞制药有限公司 | 口服盐酸二甲双胍缓释剂及其制备方法 |
CN1478770A (zh) * | 2002-08-29 | 2004-03-03 | 中国科学院上海药物研究所 | 一类1,3-二羰基化合物及它的制备和用途 |
CN101277719A (zh) * | 2005-09-29 | 2008-10-01 | 第一三共株式会社 | 包含胰岛素增敏剂的药剂 |
Non-Patent Citations (4)
Title |
---|
H. -U. DEMUTH. ET AL.: "Type 2 diabetes-Therapy with dipeptidyl peptidase IV inhibitors", BIOCHIM. BIOPHVS. ACTA, vol. 1751, 2005, pages 33 - 44 |
HANS-ULRICH DEMUTH ET AL.: "Type 2 diabetes-Therapy with dipeptidyl peptidase IV inhibitors", BIOCHIMICA ET BIOPHYSICAACTA, vol. 1751, 2005, pages 33 - 44, XP027627872 * |
K. AUGUSTYNS. ET AL.: "Inhibitors of proline-specific dipeptidyl peptidases: DPP4 inhibitors as a novel approach for the treatment of Type 2 diabetes", EXPERT OPIN. THER. PATANTS, vol. 15, 2005, pages 1387 - 1407 |
See also references of EP2402342A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI494313B (zh) * | 2010-12-29 | 2015-08-01 | Jiangsu Hengrui Medicine Co | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN101849944A (zh) | 2010-10-06 |
US8476272B2 (en) | 2013-07-02 |
CN102365284A (zh) | 2012-02-29 |
US20120010211A1 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5779566B2 (ja) | ジペプチジルペプチダーゼ−4インヒビターとメトホルミンとを組み合わせた医薬組成物 | |
US20120059011A1 (en) | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone | |
KR20120104523A (ko) | 디펩티딜 펩티다제―4 억제제와 피오글리타존의 조합물의 제약 조성물 | |
WO2010111905A1 (zh) | 治疗2型糖尿病的药物组合物 | |
EP2402342B1 (en) | Pharmaceutical composition for treatment of 2 type diabetes | |
TWI462925B (zh) | 治療2型糖尿病的藥物組合物 | |
CN101919851B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
TWI484955B (zh) | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 | |
TWI494313B (zh) | 治療包括人類之哺乳動物中第2型糖尿病的醫藥組成物 | |
WO2011009360A1 (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 | |
CN101904840B (zh) | 治疗哺乳动物包括人2型糖尿病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080014187.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10758007 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2010758007 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010758007 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13257945 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012502429 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7003/CHENP/2011 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Ref document number: 200910129595.X Country of ref document: CN Date of ref document: 20110906 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED |
|
ENP | Entry into the national phase |
Ref document number: 20117025744 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011140785 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1015469 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1015469 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110929 |